trial · primary record
Trastuzumab deruxtecan
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 477 |
| Primary completion | 2027-03-23 |
| Primary endpoint | Objective Response Rate (ORR) |
| Registry ID | NCT04482309 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:06.435Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04482309
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Trastuzumab deruxtecan · compound